Matching articles for "Pravachol"

Comparison Table: Some Lipid-Lowering Drugs (online only)

   
The Medical Letter on Drugs and Therapeutics • September 19, 2022;  (Issue 1659)
...
View the Comparison Table: Some Lipid-Lowering Drugs
Med Lett Drugs Ther. 2022 Sep 19;64(1659):e152-6 | Show Full IntroductionHide Full Introduction

Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol

   
The Medical Letter on Drugs and Therapeutics • April 6, 2020;  (Issue 1595)
The FDA has approved the oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid for use alone (Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption...
The FDA has approved the oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid for use alone (Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption inhibitor ezetimibe (Nexlizet) as an adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-cholesterol (LDL-C). Bempedoic acid is the first ACL inhibitor to be approved in the US.
Med Lett Drugs Ther. 2020 Apr 6;62(1595):53-5 | Show Full IntroductionHide Full Introduction

Expanded Table: Statins (online only)

   
The Medical Letter on Drugs and Therapeutics • September 23, 2019;  (Issue 1581)
...
View the Expanded Table: Statins
Med Lett Drugs Ther. 2019 Sep 23;61(1581):e152 | Show Full IntroductionHide Full Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • February 11, 2019;  (Issue 1565)
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force have recently been published. See Table 1 for a brief summary of their...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force have recently been published. See Table 1 for a brief summary of their recommendations.
Med Lett Drugs Ther. 2019 Feb 11;61(1565):17-24 | Show Full IntroductionHide Full Introduction

Expanded Table: Lipid-Lowering Drugs (online only)

   
The Medical Letter on Drugs and Therapeutics • February 11, 2019;  (Issue 1565)
...
View the Expanded Table: Lipid-Lowering Drugs
Med Lett Drugs Ther. 2019 Feb 11;61(1565):e24-30 | Show Full IntroductionHide Full Introduction

In Brief: Pitavastatin Magnesium (Zypitamag) for Hyperlipidemia

   
The Medical Letter on Drugs and Therapeutics • June 18, 2018;  (Issue 1549)
The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium (Zypitamag – Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin...
The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium (Zypitamag – Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin magnesium bioequivalent to pitavastatin calcium (Livalo), which was approved in 2009.1

Statins remain the treatment of choice for most patients who require lipid-lowering therapy. Taken as an adjunct to diet modification, increased exercise, and smoking cessation, statins can reduce the risk of primary and secondary cardiovascular events and death in patients with or at high risk for atherosclerotic cardiovascular disease.2 Even in patients at low risk for cardiovascular disease, treatment with a statin can significantly reduce the incidence of cardiovascular events.3

Controlled trials in patients with cardiovascular disease have shown that high-intensity statin therapy (defined as reducing LDL-cholesterol [LDL-C] by ≥50% on average) reduces the incidence of cardiac events, stroke, and coronary death significantly more than less intensive regimens. In one meta-analysis, each additional 1 mmol/L (39 mg/dL) reduction in LDL-C was associated with a 20% reduction in major vascular events and a 10% reduction in all-cause mortality.4 In a randomized trial in 13,054 Japanese patients with stable coronary artery disease, over a median follow-up of 3.9 years, patients taking pitavastatin calcium 4 mg daily were significantly less likely than those taking 1 mg daily to have a cardiovascular event (4.3% vs 5.4%).5

Approval of pitavastatin magnesium was based on the results of trials with pitavastatin calcium; no new efficacy trials were required. The Medical Letter's review of pitavastatin calcium concluded that recommended doses of the drug had not been shown to decrease LDL-C more than other statins with longer safety records and there was no good reason to use it. That conclusion applies to pitavastatin magnesium as well.

  1. Pitavastatin (Livalo) – the seventh statin. Med Lett Drugs Ther 2010; 52:57.
  2. Lipid-lowering drugs. Med Lett Drugs Ther 2016; 58:133.
  3. CTT Collaboration et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581.
  4. CTT Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670.
  5. I Taguchi et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation 2018; 137:1997.


Download complete U.S. English article

Med Lett Drugs Ther. 2018 Jun 18;60(1549):106 | Show Full IntroductionHide Full Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • October 24, 2016;  (Issue 1506)
Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment...
Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment of most patients who require lipid-lowering therapy.
Med Lett Drugs Ther. 2016 Oct 24;58(1506):133-40 | Show Full IntroductionHide Full Introduction

Alirocumab (Praluent) to Lower LDL-Cholesterol

   
The Medical Letter on Drugs and Therapeutics • August 17, 2015;  (Issue 1475)
The FDA has approved the subcutaneously injected PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor alirocumab (Praluent – Sanofi/Regeneron) as an adjunct to diet and maximally...
The FDA has approved the subcutaneously injected PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor alirocumab (Praluent – Sanofi/Regeneron) as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol (LDL-C). It was not approved for general use in statin-intolerant patients. Alirocumab is the first PCSK9 inhibitor to be approved in the US. Evolocumab (Repatha – Amgen), another PCSK9 inhibitor, was recently approved in Europe and has been recommended for approval for the same indications in the US by an FDA Advisory Committee.
Med Lett Drugs Ther. 2015 Aug 17;57(1475):113-5 | Show Full IntroductionHide Full Introduction

Drugs for Lipids

   
The Medical Letter on Drugs and Therapeutics • January 1, 2014;  (Issue 137)
HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL...
HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL receptors, which in turn increases uptake and clearance of LDL-C from the blood. Statins also lower very low-density lipoprotein cholesterol (VLDL-C) and triglycerides. Most statins increase high-density lipoprotein cholesterol (HDL-C), but only modestly.
Treat Guidel Med Lett. 2014 Jan;12(137):1-6 | Show Full IntroductionHide Full Introduction

New Simvastatin Dosing Recommendations

   
The Medical Letter on Drugs and Therapeutics • August 8, 2011;  (Issue 1370)
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or...
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone (Zocor, and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor).
Med Lett Drugs Ther. 2011 Aug 8;53(1370):61-2 | Show Full IntroductionHide Full Introduction

Drugs for Lipids

   
The Medical Letter on Drugs and Therapeutics • March 1, 2011;  (Issue 103)
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. Lipid-regulating drugs must be taken...
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels in 2-3 weeks.
Treat Guidel Med Lett. 2011 Mar;9(103):13-20 | Show Full IntroductionHide Full Introduction

Pitavastatin (Livalo) - The Seventh Statin

   
The Medical Letter on Drugs and Therapeutics • July 26, 2010;  (Issue 1343)
The FDA has approved the marketing of pitavastatin (Livalo – Kowa), an HMG-CoA reductase inhibitor (“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has been available in...
The FDA has approved the marketing of pitavastatin (Livalo – Kowa), an HMG-CoA reductase inhibitor (“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has been available in Japan since 2003. All of the statins now available in the US are listed in the table on page 58.
Med Lett Drugs Ther. 2010 Jul 26;52(1343):57-8 | Show Full IntroductionHide Full Introduction

When a Statin Fails

   
The Medical Letter on Drugs and Therapeutics • July 27, 2009;  (Issue 1317)
The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) and considers a value...
The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) and considers a value <70 mg/dL (1.8 mmol/L) a reasonable goal for patients at very high risk.
Med Lett Drugs Ther. 2009 Jul 27;51(1317):58-60 | Show Full IntroductionHide Full Introduction

Drug Interactions with Simvastatin

   
The Medical Letter on Drugs and Therapeutics • October 20, 2008;  (Issue 1297)
A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin (Zocor, and others) and green tea. Since it became...
A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin (Zocor, and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin (Lipitor) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.
Med Lett Drugs Ther. 2008 Oct 20;50(1297):83-4 | Show Full IntroductionHide Full Introduction

Which Statin?

   
The Medical Letter on Drugs and Therapeutics • April 21, 2008;  (Issue 1284)
Advertisements for atorvastatin (Lipitor), the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much...
Advertisements for atorvastatin (Lipitor), the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much lower retail price or lower co-pay than atorvastatin.
Med Lett Drugs Ther. 2008 Apr 21;50(1284):29-31 | Show Full IntroductionHide Full Introduction

Drugs for Lipids

   
The Medical Letter on Drugs and Therapeutics • February 1, 2008;  (Issue 66)
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for...
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for lifestyle changes; a combination of diet, exercise and lipid-lowering drugs is optimal for prevention of coronary disease. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoprotein levels return to pretreatment levels in 2-3 weeks.
Treat Guidel Med Lett. 2008 Feb;6(66):9-16 | Show Full IntroductionHide Full Introduction

Statins for High-Risk Patients without Heart Disease or High Cholesterol

   
The Medical Letter on Drugs and Therapeutics • January 2, 2006;  (Issue 1225)
The FDA recently approved the use of atorvastatin (Lipitor) to reduce the risk of heart attack and stroke in patients without heart disease who have type 2 diabetes plus other risk factors, with or without...
The FDA recently approved the use of atorvastatin (Lipitor) to reduce the risk of heart attack and stroke in patients without heart disease who have type 2 diabetes plus other risk factors, with or without hypercholesterolemia. The agency also approved the drug's use to reduce the risk of stroke in high-risk nondiabetic patients without heart disease, whether or not they have hypercholesterolemia. Similar indications were previously approved for simvastatin (Zocor).
Med Lett Drugs Ther. 2006 Jan 2;48(1225):1-2 | Show Full IntroductionHide Full Introduction

Omega-3 Polyunsaturated Fatty Acids (Omacor) for Hypertriglyceridemia

   
The Medical Letter on Drugs and Therapeutics • November 7, 2005;  (Issue 1221)
A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations...
A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations (>=500 mg/dL). Omacor is a combination of the ethyl esters of icosapentaenoic (EPA) and docosahexaenoic (DHA) acids. It is the first drug derived from omega-3 PUFAs to be sold by prescription.
Med Lett Drugs Ther. 2005 Nov 7;47(1221):91-2 | Show Full IntroductionHide Full Introduction

Drugs for Lipids

   
The Medical Letter on Drugs and Therapeutics • March 1, 2005;  (Issue 31)
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. In controlled trials in patients with...
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. In controlled trials in patients with coronary disease, some of these drugs have reduced mortality by 20% to 30%.
Treat Guidel Med Lett. 2005 Mar;3(31):15-22 | Show Full IntroductionHide Full Introduction

Safety of Aggressive Statin Therapy

   
The Medical Letter on Drugs and Therapeutics • November 22, 2004;  (Issue 1196)
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Med Lett Drugs Ther. 2004 Nov 22;46(1196):93-5 | Show Full IntroductionHide Full Introduction

Cholesterol Rethink for High-Risk Patients

   
The Medical Letter on Drugs and Therapeutics • May 10, 2004;  (Issue 1182)
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been...
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
Med Lett Drugs Ther. 2004 May 10;46(1182):37-9 | Show Full IntroductionHide Full Introduction

Rosuvastatin - a New Lipid-lowering Drug

   
The Medical Letter on Drugs and Therapeutics • October 13, 2003;  (Issue 1167)
Rosuvastatin (Crestor - AstraZeneca), an HMG-CoA reductase inhibitor (or "statin"), was recently approved by the FDA for lowering serum cholesterol and triglyceride concentrations and raising HDL cholesterol...
Rosuvastatin (Crestor - AstraZeneca), an HMG-CoA reductase inhibitor (or "statin"), was recently approved by the FDA for lowering serum cholesterol and triglyceride concentrations and raising HDL cholesterol levels. Rosuvastatin, like other statins, inhibits the enzyme that catalyzes the rate-limiting step in cholesterol synthesis, but it is claimed to be more potent than the others. All of these drugs must be taken indefinitely; if they are discontinued, lipid levels return to baseline.
Med Lett Drugs Ther. 2003 Oct 13;45(1167):81-3 | Show Full IntroductionHide Full Introduction

Drugs For Lipid Disorders

   
The Medical Letter on Drugs and Therapeutics • August 1, 2003;  (Issue 12)
Drugs that lower low-density lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and also improve vasodilatation. In controlled...
Drugs that lower low-density lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and also improve vasodilatation. In controlled trials in patients with coronary disease, they have reduced mortality by 30% to 40%. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipid levels return to pretreatment levels in 2-3 weeks.
Treat Guidel Med Lett. 2003 Aug;1(12):77-82 | Show Full IntroductionHide Full Introduction

Three New Drugs for Hyperlipidemia

   
The Medical Letter on Drugs and Therapeutics • March 3, 2003;  (Issue 1151)
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol....
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin (Mevacor, and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.
Med Lett Drugs Ther. 2003 Mar 3;45(1151):17-9 | Show Full IntroductionHide Full Introduction

Generic Lovastatin - Note

   
The Medical Letter on Drugs and Therapeutics • October 15, 2001;  (Issue 1115)
Because of a last minute change in an FDA ruling, generic lovastatin will not be available until after December 15, contrary to the statement in the September 17 Medical Letter article on Substituing for...
Because of a last minute change in an FDA ruling, generic lovastatin will not be available until after December 15, contrary to the statement in the September 17 Medical Letter article on Substituing for Cerivastatin (vol. 23, page 79)
Med Lett Drugs Ther. 2001 Oct 15;43(1115):90 | Show Full IntroductionHide Full Introduction

Substituting For Cerivastatin (Baycol)

   
The Medical Letter on Drugs and Therapeutics • September 17, 2001;  (Issue 1113)
Full-page newspaper advertisements are urging patients with high cholesterol levels who are stopping Baycol (cerivastatin) to ask their doctors about Pravachol (pravastatin), Lipitor (atorvastatin), Zocor...
Full-page newspaper advertisements are urging patients with high cholesterol levels who are stopping Baycol (cerivastatin) to ask their doctors about Pravachol (pravastatin), Lipitor (atorvastatin), Zocor (simvastatin) or Lescol (fluvastatin). Some advertisements come with a coupon for free medication. Lovastatin, which is available generically, has not appeared in similar advertisements. Cerivastatin was withdrawn from the market on August 8 because of post-marketing reports of 31 cases of fatal rhabdomyolysis.
Med Lett Drugs Ther. 2001 Sep 17;43(1113):79-80 | Show Full IntroductionHide Full Introduction

Choice of Lipid-Regulating Drugs

   
The Medical Letter on Drugs and Therapeutics • May 28, 2001;  (Issue 1105)
New recommendations for drug treatment of hypercholesterolemia, if widely followed, will lead to a marked increase in the number of people taking lipid-regulating...
New recommendations for drug treatment of hypercholesterolemia, if widely followed, will lead to a marked increase in the number of people taking lipid-regulating drugs.
Med Lett Drugs Ther. 2001 May 28;43(1105):43-8 | Show Full IntroductionHide Full Introduction

Choice of Lipid-lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • December 18, 1998;  (Issue 1042)
Drugs that lower-density-lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, improve coronary vasodilatation, and decrease...
Drugs that lower-density-lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, improve coronary vasodilatation, and decrease mortality from coronary heart disease. All of these drugs must be continued indefinitely; when they are stopped, plasma cholesterol concentrations generally return to pretreatment levels. Elevated serum triglyceride concentrations appear to be an independent risk factor for cardiovascular disease in both women and men, but direct evidence of clinical benefit from triglyceride reduction is lacking.
Med Lett Drugs Ther. 1998 Dec 18;40(1042):117-22 | Show Full IntroductionHide Full Introduction

Fenofibrate for Hypertriglyceridemia

   
The Medical Letter on Drugs and Therapeutics • July 3, 1998;  (Issue 1030)
Micronized fenofibrate (Tricor - Abbott), a fibric acid derivative structurally similar to clofibrate (Atromid-S, and others) and gemfibrozil (Lopid, and others), has been approved by the FDA for treatment of...
Micronized fenofibrate (Tricor - Abbott), a fibric acid derivative structurally similar to clofibrate (Atromid-S, and others) and gemfibrozil (Lopid, and others), has been approved by the FDA for treatment of hypertriglyceridemia. Increased serum triglyceride concentrations have been associated with an increased risk of coronary heart disease (J Jeppesen et al, Circulation, 97:1029, 1998).
Med Lett Drugs Ther. 1998 Jul 3;40(1030):68-9 | Show Full IntroductionHide Full Introduction

Cerivastatin for Hypercholesterolemia

   
The Medical Letter on Drugs and Therapeutics • January 16, 1998;  (Issue 1018)
Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl...
Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl pyridinyl-substituted heptanoic acid.
Med Lett Drugs Ther. 1998 Jan 16;40(1018):13-4 | Show Full IntroductionHide Full Introduction

Atorvastatin - A New Lipid-lowering Drug

   
The Medical Letter on Drugs and Therapeutics • March 28, 1997;  (Issue 997)
Atorvastatin (Lipitor - Parke-Davis), an HMG-CoA reductase inhibitor (or 'statin'), was recently approved by the US Food and Drug Administration for treatment of primary hypercholesterolemia and mixed...
Atorvastatin (Lipitor - Parke-Davis), an HMG-CoA reductase inhibitor (or 'statin'), was recently approved by the US Food and Drug Administration for treatment of primary hypercholesterolemia and mixed dyslipidemia. A single stereoisomer of a pyrrole derivative, the new drug is chemically different from other statins.
Med Lett Drugs Ther. 1997 Mar 28;39(997):29-31 | Show Full IntroductionHide Full Introduction

Choice of Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • August 2, 1996;  (Issue 980)
Drugs that lower elevated plasma cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and may also improve coronary vasodilatation (JW Jukema et...
Drugs that lower elevated plasma cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and may also improve coronary vasodilatation (JW Jukema et al, circulation, 91:2528, 1995: CB Treasure er al, N Engl J Med, 332:481, 1995; TJ Anderson et al, N Engl J Med, 332:488, 1995). All these drugs must be continued indefinitely; when htey are stopped, plasma cholesterol concentrations generally return to pretreatment levels.
Med Lett Drugs Ther. 1996 Aug 2;38(980):67-70 | Show Full IntroductionHide Full Introduction

Fluvastatin for Lowering Cholesterol

   
The Medical Letter on Drugs and Therapeutics • May 27, 1994;  (Issue 923)
Fluvastatin (Lescol - Sandoz), an HMG-CoA reductase inhibitor, was recently marketed in the USA for treatment of hypercholesterolemia. A synthetic mevalonolactone derivative, it is chemically distinct from...
Fluvastatin (Lescol - Sandoz), an HMG-CoA reductase inhibitor, was recently marketed in the USA for treatment of hypercholesterolemia. A synthetic mevalonolactone derivative, it is chemically distinct from previously available drugs in this class.
Med Lett Drugs Ther. 1994 May 27;36(923):45-6 | Show Full IntroductionHide Full Introduction

Choice of Cholesterol-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • March 5, 1993;  (Issue 891)
Lowering elevated serum cholesterol concentrations can slow progression and sometimes cause regression of atherosclerotic lesions. Most authorities advise patients with high cholesterol concentrations to eat...
Lowering elevated serum cholesterol concentrations can slow progression and sometimes cause regression of atherosclerotic lesions. Most authorities advise patients with high cholesterol concentrations to eat less fat and less cholesterol and, when appropriate, to lose weight. If these measures do not lower serum lipids sufficiently, drugs are frequently added to the regimen. When drugs are discontinued, serum cholesterol concentrations generally return to pretreatment levels.
Med Lett Drugs Ther. 1993 Mar 5;35(891):19-22 | Show Full IntroductionHide Full Introduction

Pravastatin, Simvastatin, and Lovastatin For Serum Cholesterol Concentrations

   
The Medical Letter on Drugs and Therapeutics • June 12, 1992;  (Issue 872)
Pravastatin - Bristol-Myers Squibb) and simvastatin (Zocor -Merck), two new inhibitors of cholesterol synthesis similar to lovastatin (Mevacor - Merck), have now been marketed in the USA for treatment of...
Pravastatin - Bristol-Myers Squibb) and simvastatin (Zocor -Merck), two new inhibitors of cholesterol synthesis similar to lovastatin (Mevacor - Merck), have now been marketed in the USA for treatment of hypercholesterolemia. Lovastatin (Medical Letter, 29:99, 1987) is the most frequently prescribed of all cholesterol-lowering drugs in the USA. Pravastatin and simvastatin were previously reviewed in The Medical Letter when they became available in Canada (volume 33, page 18, 1991).
Med Lett Drugs Ther. 1992 Jun 12;34(872):57-8 | Show Full IntroductionHide Full Introduction

Pravastatin And Simvastatin for Hypercholesterolemia

   
The Medical Letter on Drugs and Therapeutics • March 8, 1991;  (Issue 839)
Pravastatin (Pravachol - Bristol-Myers Squibb) and simvastatin (Zocor - Merck), two new inhibitors of cholesterol synthesis similar to lovastatin (Mevacor - Merck), have been marketed in Canada and several...
Pravastatin (Pravachol - Bristol-Myers Squibb) and simvastatin (Zocor - Merck), two new inhibitors of cholesterol synthesis similar to lovastatin (Mevacor - Merck), have been marketed in Canada and several European countries and may soon be available in the USA for treatment of high plasma cholesterol concentrations. Drugs already marketed here for this indication were recently reviewed in The Medical Letter (Volume 33, page 1, January 11, 1991).
Med Lett Drugs Ther. 1991 Mar 8;33(839):18-20 | Show Full IntroductionHide Full Introduction